Anti-mitochondrial M2 Antibodies Enhance the Risk of Supraventricular Arrhythmias in Patients with Elevated Hepatobiliary Enzyme Levels

Hiroki Konishi¹, Koji Fukuzawa^{1,2}, Shumpei Mori¹, Seimi Satomi-Kobayashi¹,
Kunihiko Kiuchi^{1,2}, Atsushi Suzuki¹, Yoshihiko Yano³, Akihiro Yoshida¹ and Ken-ichi Hirata^{1,2}

Abstract

Objective Supraventricular arrhythmias are commonly detected in patients with anti-mitochondrial antibody M2 (AMA-M2)-associated myopathy. However, the prevalence of supraventricular arrhythmias in unselected AMA-M2-positive patients and the impact of AMA-M2 on supraventricular arrhythmias have yet to be fully investigated.

Methods We analyzed 384 patients (116 men; age, 60 [48-69] years), who underwent AMA-M2 testing following the detection of elevated hepatobiliary enzymes. Supraventricular arrhythmias involving atrial fibrillation, atrial flutter, atrial tachycardia, sick sinus syndrome, and atrial standstill were confirmed by a 12-lead electrocardiogram, 24-hour ambulatory monitoring, and physician-assigned diagnoses within the three years before and two years after the AMA-M2 test.

Results Seventy-seven (20%) patients were positive for AMA-M2. The prevalence of supraventricular arrhythmias among AMA-M2-positive patients was higher than that among AMA-M2-negative patients (14% vs. 6%, $p=0.008$). A univariate analysis showed that supraventricular arrhythmias were associated with AMA-M2 positivity, aging, congestive heart failure, and the CHADS₂ score. The multivariate analysis determined that AMA-M2 positivity was an independent risk factor for supraventricular arrhythmias (odds ratio 3.52, $p=0.011$). Among the AMA-M2-positive patients, the AMA-M2 titer did not differ to a statistically significant extent, regardless of the presence or absence of supraventricular arrhythmias. Multiple supraventricular arrhythmias with extremely low atrial deflections was a characteristic finding in AMA-M2-positive patients with supraventricular arrhythmias.

Conclusion AMA-M2 enhances the risk of supraventricular arrhythmias, indicating the possible involvement of the atrial myocardium and the formation of an arrhythmogenic substrate. The results highlight the need for clinical attention to supraventricular arrhythmias in AMA-M2-positive patients.

Key words: anti-mitochondrial antibody, cardiomyopathy, primary biliary cholangitis, supraventricular arrhythmia

(Intern Med 56: 1771-1779, 2017)

(DOI: 10.2169/internalmedicine.56.8183)

Introduction

Anti-mitochondrial antibodies (AMAs) are autoantibodies against several mitochondrial antigens that can be detected

in the sera from patients with primary biliary cholangitis (PBC) by immunoblotting and enzyme-linked immunosorbent assays (1). To date, nine mitochondrial antigens (M1-M9) have been reported to stimulate the production of the corresponding antibodies, AMA-M1 to AMA-M9 (2).

¹Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Japan, ²Section of Arrhythmia, Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Japan and ³Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Japan

Received for publication August 29, 2016; Accepted for publication November 28, 2016

Correspondence to Dr. Koji Fukuzawa, kfuku@med.kobe-u.ac.jp

Among these antigens, AMA-M2 reacts with the pyruvate dehydrogenase E2 complex. This target antigen is located in the inner mitochondrial matrix and catalyzes the oxidative decarboxylation of keto acid substrates (3, 4). AMA-M2 is detected in 90-95% of patients with PBC (4). Skeletal muscular involvement manifesting as progressive muscular weakness with elevated levels of muscle-associated enzymes and respiratory failure has been reported in patients with AMA-M2 (5-7). Although the mechanism underlying the development of AMA-M2-associated myopathy has yet to be clarified, it is considered likely that mitochondrial dysfunction and autoimmunity, which are maintained by the predominant autoreactive T cells, are associated with the skeletal muscular damage (8). Furthermore, concomitant cardiac involvement has been reported in patients with AMA-M2-associated myopathy, as revealed by ventricular dysfunction and/or various arrhythmias (5, 6). Among patients with such arrhythmias, the prevalence of supraventricular arrhythmias has been reported to be high (5), which might suggest a preferential atrial myocardial involvement. However, the prevalence of supraventricular arrhythmias in unselected AMA-M2-positive patients has yet to be systematically investigated in the clinical setting. Accordingly, little is known regarding the clinical impact of AMA-M2 on supraventricular arrhythmias. The objective of this study was to clarify the prevalence of supraventricular arrhythmias in AMA-M2-positive patients, regardless of skeletal muscular involvement. The impact of AMA-M2 on supraventricular arrhythmias was then investigated to estimate the atrial myocardial involvement and the formation of arrhythmogenic substrates.

Materials and Methods

Study population

We retrospectively analyzed 384 consecutive patients who underwent AMA-M2 testing for the further examination of elevated hepatobiliary enzyme levels between August 2012 and July 2014.

Elevated hepatobiliary enzyme levels were defined by any of the following conditions: aspartate aminotransferase (AST) >32 IU/L, alanine aminotransferase (ALT) >37 IU/L, alkaline phosphatase (ALP) >100 IU/L, or γ -glutamyltranspeptidase (γ -GTP) >51 IU/L. In all cases, the clinical history was acquired and a laboratory analysis was performed. Congestive heart failure was defined by the presence of symptoms of heart failure classified as New York Heart Association class $\geq$ II or a left ventricular ejection fraction of <40%. Hypertension was defined as a systolic blood pressure of $\geq$ 140 mmHg, a diastolic pressure of $\geq$ 90 mmHg, or the use of antihypertensive agents. Diabetes mellitus was defined as a fasting glucose level of $\geq$ 126 mg/dL, a random non-fasting glucose level of $\geq$ 200 mg/dL, a hemoglobin A1c level of $\geq$ 6.5%, or the use of oral hypoglycemic agents or insulin. The CHADS₂ score was generated by assigning one point each for the following factors: a history of congestive heart fail-

ure, hypertension, age $\geq$ 75 years, and diabetes mellitus, and by assigning two points for a history of stroke or transient ischemic attack (9).

The present study was performed according to standard clinical practice and complied with the Declaration of Helsinki. All of the study participants provided their informed consent. The research protocol was approved by the Human Ethical Committee at Kobe University Hospital (No. 1830).

Laboratory analysis

The following clinical laboratory parameters were evaluated: white blood cell count, hemoglobin, platelet count; liver function parameters (including total bilirubin, AST, ALT, ALP, and γ -GTP); creatinine kinase (CK); albumin; electrolytes (including sodium, potassium, and chloride); renal function parameters (including blood urea nitrogen, creatinine, and the estimated glomerular filtration rate [eGFR]); C-reactive protein, and AMA-M2. The eGFR was obtained from the equation defined by the Japanese Society of Nephrology: $\text{eGFR} = 194 \times \text{serum creatinine level (mg/dL)}^{-1.094} \times \text{age (years)}^{-0.287}$ (if female $\times$ 0.739) mL/min/1.73 m² (10).

The AMA-M2 titer was evaluated using a commercially available chemiluminescent enzyme immuno-assay (Medical & Biological Laboratories, Nagoya, Japan). AMA-M2 positivity was defined as an AMA-M2 titer of $\geq$ 7.0 IU/mL.

Definition of arrhythmias

Arrhythmias were detected based on a 12-lead electrocardiogram (ECG), 24-hour ambulatory monitoring, and/or a physician-assigned diagnosis that was found in the medical records within three years before and two years after AMA-M2 testing. Furthermore, asymptomatic arrhythmias documented on ECG monitoring during hospitalization and in implanted devices were considered to be arrhythmias. In this situation, arrhythmias lasting for >30 seconds were included.

Supraventricular arrhythmias were defined as supraventricular tachyarrhythmias involving atrial fibrillation (AF), atrial flutter (AFL), and atrial tachycardia (AT), and supraventricular bradyarrhythmias involving sick sinus syndrome (SSS) and atrial standstill. AF was defined as irregular R-R intervals with typical fibrillation in the baseline without distinct P-waves. AFL was defined as the presence of characteristic regular flutter waves with a cycle length of $\leq$ 250 ms without an isoelectric baseline between the atrial deflections in at least a single lead. AT was defined as a regular ectopic P-wave with a cycle length of $\leq$ 400 ms and distinct P-waves that differed from normal sinus rhythm. SSS was defined as sinus bradycardia <50 bpm, sinus arrest of >3.0 seconds, and/or sinoatrial exit block. Atrial standstill was defined as the continuous disappearance of any atrial deflections in the baseline with an escape rhythm, representing the electrical or mechanical silence of the atrial excitation. Ventricular arrhythmias were defined as sustained ventricular tachycardia lasting for >30 seconds or the detection of ventricular fibrillation on a device recording.

Table 1. Comparison of Baseline Characteristics.

Variable	AMA-M2 positive group n=77	AMA-M2 negative group n=307	p value
Age, years	60 (51-69)	60 (47-70)	0.512
Male gender, n (%)	4 (5)	112 (36)	<0.001
Body mass index, kg/m ²	21.9 (18.8-25.4)	21.9 (19.3-24.6)	0.937
Congestive heart failure, n (%)	7 (9)	13 (4)	0.082
Hypertension, n (%)	24 (31)	85 (28)	0.545
Age ≥75, n (%)	8 (10)	41 (13)	0.314
Diabetes mellitus, n (%)	11 (14)	74 (24)	0.064
Stroke/transient ischemic attack, n (%)	1 (1)	7 (2)	0.500
CHADS ₂ score	0 (0-1)	1 (0-1)	0.404

Nonparametric continuous variables are expressed as median values (lower quartile value-upper quartile value).

AMA-M2: anti-mitochondrial antibody M2

Baseline 12-lead ECG

We hypothesized that if significant latent atrial muscular damage due to AMA-M2 was present, it could be reflected in the baseline 12-lead ECG findings as a low P-wave amplitude. To evaluate this type of latent electrical remodeling in either the atrium or ventricle, we retrospectively analyzed the subgroup of patients with 12-lead ECG data by investigating the following parameters of the baseline 12-lead ECG. In addition to the heart rate, the PR interval, P-wave amplitude, P-wave duration, Morris index, QRS duration, QRS axis, QT interval, corrected QT interval, sum of the amplitude of the S-wave in lead V1 and the R-wave in lead V5 (SV1+RV5), and the prevalence of P-dextrocardiale and P-sinistocardiale were measured. We also analyzed the presence of complete right or left bundle branch block.

The P-wave amplitude, P-wave duration, and Morris index were measured using lead V1. The Morris index was derived by multiplying the depth of the terminal P-wave deflection (mm) by its duration (s). The P-dextrocardiale was defined as a P-wave-positive component of ≥0.25 mV in leads II, III, and aVF, or a P-wave-positive component of ≥0.2 mV in lead V1 or V2, or a P-wave duration of ≤100 ms in lead V1, reflecting the overloading of the right atrium. The P-sinistocardiale was defined as a Morris index of ≥0.04 or a P-wave duration of ≥120 ms in lead II, reflecting the overloading of the left atrium.

Transthoracic echocardiography

Based on the hypothesis that latent mechanical remodeling of either the atrium or ventricle could be detected as morphological changes, we retrospectively analyzed the subgroup of patients for whom echocardiographic data was available. All of the transthoracic echocardiographic studies were performed using commercially available echocardiographic systems (Aplo Artida, Toshiba Medical Systems, Tochigi, Japan; Vivid E9, GE Vingmed, Horten, Norway; iE 33, Philips Healthcare, Andover, USA). Using the standard parasternal view, we measured the dimensions of the left ventricle and the left atrium according to the American Soci-

ety of Echocardiography guidelines (11). Each value was indexed by dividing it by the body surface area. The early diastolic (E) and atrial filling (A) wave velocities of the trans-mitral inflow, as well as E-wave deceleration time and E/A, were measured using a pulsed-wave Doppler recording in the standard apical three- or four-chamber view.

Statistical analysis

Nonparametric continuous variables were expressed as median values with interquartile ranges. Categorical variables were expressed as a percentage. Intergroup differences were evaluated using the Mann-Whitney U test for nonparametric continuous variables and a chi-squared test for categorical variables. The univariate relationships between the supraventricular arrhythmias and variables were evaluated by a logistic regression analysis. A multivariate logistic regression analysis was performed using the maximum likelihood method to identify the independent risk factors for supraventricular arrhythmias. The association was shown as an odds ratio with 95% confidence intervals and p values. All of the statistical analyses were performed using the SPSS software program (version 20.0; IBM, Chicago, USA). p values of <0.05 were considered to indicate statistical significance in all of the analyses.

Results

In total, 384 patients (116 men; median age, 60 [48-69] years) were enrolled in this study. Seventy-seven of the patients were positive for AMA-M2. Comparisons of the baseline characteristics of the AMA-M2-positive and AMA-M2-negative patients are shown in Table 1. The proportion of male patients was significantly lower among the AMA-M2-positive patients. The CHADS₂ scores of the two groups did not differ to a statistically significant extent.

Among the laboratory parameters, the white blood cell count, hemoglobin level, and eGFR were significantly lower, and the level of alanine aminotransferase was significantly higher in the AMA-M2-positive patients. No significant differences were documented for the other laboratory parame-

Table 2. Comparison of Laboratory Parameters.

Variable	AMA-M2 positive group n=77	AMA-M2 negative group n=307	p value
White blood cell, $\times 10^3/\mu\text{L}$	56 (46-65)	60 (49-76)	0.042
Hemoglobin, g/dL	12.5 (11.2-13.2)	12.8 (11.3-14.0)	0.048
Platelet, $\times 10^4/\mu\text{L}$	21.3 (17.1-26.8)	21.6 (16.0-26.9)	1.000
Total bilirubin, mg/dL	0.7 (0.6-1.0)	0.7 (0.5-1.0)	0.441
Aspartate aminotransferase, IU/L	37 (25-58)	37 (25-63)	0.984
Alanine aminotransferase, IU/L	27 (19-53)	38 (23-71)	0.011
Alkaline phosphatase, IU/L	306 (214-464)	307 (229-466)	0.920
γ -glutamyltranspeptidase, IU/L	72 (28-152)	57 (29-148)	0.503
Creatinine kinase, IU/L	72 (47-140)	81 (46-133)	0.782
Albumin, g/dL	4.1 (3.4-4.3)	4.0 (3.4-4.4)	0.714
Sodium, mEq/L	140 (139-142)	140 (138-141)	0.254
Potassium, mEq/L	4.1 (3.8-4.3)	4.1 (3.8-4.4)	0.943
Chloride, mEq/L	105 (104-107)	105 (103-107)	0.227
Blood urea nitrogen, mg/dL	14.0 (11.1-17.4)	14.0 (11.0-17.0)	0.881
Creatinine, mg/dL	0.62 (0.58-0.78)	0.68 (0.56-0.84)	0.421
eGFR, mL/min/1.73 m ²	74.0 (57.1-85.2)	77.7 (63.5-93.5)	0.043
C-reactive protein, mg/dL	0.15 (0.58-0.78)	0.14 (0.56-0.84)	0.825
AMA-M2 titer, IU/mL	106.0 (20.3-195.0)	1.4 (1.4-4.9)	<0.001

Nonparametric continuous variables are expressed as median values (lower quartile value-upper quartile value).

AMA-M2: anti-mitochondrial antibody M2, eGFR: estimated glomerular filtration rate

ters, including CK (Table 2).

The baseline 12-lead ECG data were available for 45 AMA-M2-positive (58%) and 202 AMA-M2-negative (66%) patients (Table 3). The 24-hour ambulatory monitoring data was available for four AMA-M2-positive and 17 AMA-M2-negative patients. The ECG monitoring data recorded during hospitalization was available for 21 AMA-M2-positive patients and 115 AMA-M2-negative patients. The ECG records from implanted devices were available for four AMA-M2-positive patients and three AMA-M2-negative patients.

Supraventricular arrhythmias were detected in 14% of the AMA-M2-positive patients, which was significantly higher than that in the AMA-M2-negative patients (Table 3). Among these patients, symptomatic supraventricular arrhythmias were documented in seven AMA-M2-positive and 10 AMA-M2-negative patients. Conversely, the frequency of ventricular arrhythmias was much lower than that of supraventricular arrhythmias and did not differ between the two groups. Among the 11 AMA-M2-positive patients with supraventricular arrhythmias, eight patients showed AF. AFL and AT were each detected in two and four patients, respectively. SSS was detected in three patients. Atrial standstill was detected in four of the 11 patients. It was notable that four patients had multiple supraventricular arrhythmias, including both tachyarrhythmias and bradyarrhythmias.

A comparison of the baseline 12-lead ECG findings revealed that the QRS duration and QRS axis were significantly lower in AMA-M2-positive patients (Table 3).

The baseline echocardiography was available for 31 AMA-M2-positive (40%) and 124 AMA-M2-negative (40%) patients. Although the left ventricular dimension indices and ejection fraction of the AMA-M2-positive and AMA-M2-

negative patients were similar, the left atrial end-systolic dimension index was significantly larger in the AMA-M2-positive patients (Table 4), suggesting the existence of possible left atrial remodeling.

Univariate analyses were performed to assess the relationship between each variable and the supraventricular arrhythmias (Table 5). The variables with p values of <0.2 in the comparison of patients with and without supraventricular arrhythmias (data not shown) were included in this analysis. The univariate analysis showed that aging, congestive heart failure, a high CHADS₂ score, and AMA-M2 positivity were significantly correlated with supraventricular arrhythmias.

To ascertain the potential independent risk factors for supraventricular arrhythmias in the present patient cohort, we next performed a multivariate logistic regression analysis. Variables with p values <0.05 in the univariate model were included in the final multivariate model. The CHADS₂ score was excluded to avoid multicollinearity. As previous reports demonstrated, supraventricular arrhythmias were observed in the limited subset of patients with AMA-M2-associated myopathy, CK was also included in this model. This analysis showed that the presence of AMA-M2, congestive heart failure and creatinine kinase were independent risk factors for supraventricular arrhythmias (Table 6).

The AMA-M2 titer of the AMA-M2-positive patients, did not differ to a statistically significant extent, regardless of the presence or absence of supraventricular arrhythmias (4.9 [1.4-20.9] IU/mL vs. 3.0 [1.4-4.9] IU/mL, p=0.777).

Few reports have described the detailed characteristics of supraventricular arrhythmias in AMA-M2-positive patients. Thus, we closely analyzed the supraventricular arrhythmias in AMA-M2-positive patients. Our clinical observations re-

Table 3. Comparison of the Electrocardiographic Findings.

Variable	AMA-M2 positive patients n=77	AMA-M2 negative patients n=307	p value
Supraventricular arrhythmias, n (%)	11 (14)	17 (6)	0.008
Atrial fibrillation, n (%)	8 (10)	13 (4)	
Atrial flutter, n (%)	2 (3)	3 (1)	
Atrial tachycardia, n (%)	4 (5)	0 (0)	
Sick sinus syndrome, n (%)	3 (4)	2 (1)	
Atrial standstill, n (%)	4 (5)	1 (0)	
Ventricular arrhythmias, n (%)	2 (3)	2 (1)	0.181
12-lead electrocardiogram	n=45	n=202	
Supraventricular arrhythmias, n (%)	7 (16)	13 (6)	0.054
Heart rate, beats/min	70 (65-79)	73 (65-82)	0.288
PR interval, ms	156 (142-176)	158 (142-174)	0.668
P-wave amplitude, mV	0.09 (0.06-0.12)	0.08 (0.06-0.10)	0.140
P-wave duration, ms	80 (70-90)	80 (65-90)	0.578
Morris index, mm-sec	0.018 (0.009-0.030)	0.017 (0.007-0.030)	0.546
QRS duration, ms	86 (80-92)	90 (83-100)	0.033
QRS axis, degree	32 (-9-66)	46 (22-67)	0.027
QT interval, ms	398 (374-415)	389 (366-410)	0.235
QTc, ms	422 (401-432)	416 (398-430)	0.311
SV1+RV5, mV	2.50 (1.89-2.90)	2.39 (1.95-2.97)	0.930
P-dextrocardiale, n (%)	0 (0)	1 (0)	0.817
P-sinistocardiale, n (%)	1 (2)	7 (3)	0.549
Complete right bundle branch block, n (%)	2 (4)	12 (6)	0.547
Complete left bundle branch block, n (%)	0 (0)	1 (0)	0.827

Nonparametric continuous variables are expressed as median values (lower quartile value-upper quartile value).

AMA-M2: anti-mitochondrial antibody M2, QTc: corrected QT interval, SV1+RV5: the sum of the amplitude of S-wave in V1 lead and R- wave in V5 lead

Table 4. Comparison of the Echocardiographic Findings.

Variable	AMA-M2 positive patients n=77	AMA-M2 negative patients n=307	p value
Echocardiography	n=31	n=124	
Supraventricular arrhythmias, n (%)	9 (29)	12 (10)	0.013
Left ventricular end-diastolic dimension index, mm/m ²	29.3 (25.2-31.9)	28.6 (26.4-31.7)	0.974
Left ventricular end-systolic dimension index, mm/m ²	17.2 (15.8-21.8)	18.1 (15.9-20.8)	0.753
Fractional shortening, %	38.6 (31.9-41.4)	36.5 (32.4-41.0)	0.708
Left atrial end-systolic dimension index, mm/m ²	26.2 (22.1-28.7)	22.6 (19.9-25.5)	0.001
Interventricular septal wall thickness, mm	9.4 (8.1-11.5)	9.8 (8.5-11.0)	0.727
Left ventricular inferolateral wall thickness, mm	9.7 (8.5-10.8)	9.8 (8.1-11.0)	0.771
Left ventricular ejection fraction, %	66.2 (60.1-71.3)	65.0 (60.0-67.8)	0.176
Transmitral flow			
Early diastolic filling (E) wave velocity, cm/s	66.8 (60.6-93.0)	66.9 (53.8-80.6)	0.185
Atrial filling (A) wave velocity, cm/s	77.4 (66.6-108.0)	67.8 (57.3-84.6)	0.024
E/A	0.90 (0.75-1.10)	0.90 (0.70-1.20)	0.937
E-wave deceleration time, ms	227 (192-276)	208 (174-262)	0.375
Severe mitral regurgitation, n (%)	1 (3)	0 (0)	0.202

Nonparametric continuous variables are expressed as median values (lower quartile value-upper quartile value).

AMA-M2: anti-mitochondrial antibody M2

revealed the following characteristics: 1) multiple supraventricular arrhythmias in a single patient, 2) the coincidence of tachyarrhythmias and bradyarrhythmias, 3) extremely low atrial deflections, and 4) frequent AF. In particular, the aver-

age value of the atrial deflections in the AMA-M2-positive AF patients was extremely low (0.03 ± 0.01 mV). Figure shows a representative case of an AMA-M2-positive patient (a 67-year-old woman) with multiple supraventricular ar-

Table 5. Univariate Relationship between Variables and the Supraventricular Arrhythmias.

Variable	Odds ratio	95% CI	p value
Age (per decade increase)	1.45	1.01-1.07	0.015
Body mass index	0.92	0.82-1.02	0.108
Congestive heart failure	4.94	1.65-14.80	0.004
Hypertension	2.00	0.91-4.39	0.083
CHADS ₂ score	1.51	1.06-2.17	0.025
Hemoglobin	0.83	0.69-1.00	0.051
Platelet	0.99	0.95-1.04	0.763
Total bilirubin	0.49	0.18-1.40	0.184
Alanine aminotransferase (per 10 IU/L elevation)	0.92	0.82-1.03	0.143
Alkaline phosphatase (per 10 IU/L elevation)	0.99	0.98-1.01	0.351
Creatinine kinase (per 50 IU/L elevation)	1.03	1.00-1.05	0.054
Chloride (per 10 mEq/L elevation)	0.47	0.18-1.22	0.121
Blood urea nitrogen (per 10 mg/dL elevation)	1.30	0.98-1.71	0.069
AMA-M2	2.84	1.27-6.35	0.011

AMA-M2: anti-mitochondrial antibody M2, CI: confidence interval

Table 6. Independent Predictors of Supraventricular Arrhythmias.

Variable	Odds ratio	95% CI	p value
Age (per decade increase)	1.42	1.00-2.04	0.053
Congestive heart failure	4.87	1.35-17.65	0.016
Creatinine kinase (per 50 IU/L elevation)	1.03	1.00-1.06	0.028
AMA-M2	3.52	1.34-9.24	0.011

AMA-M2: anti-mitochondrial antibody M2, CI: confidence interval

rhythmias, in whom AF, AT, and atrial standstill with dilated atria were present. Notably, the voltage of the atrial deflections in these multiple supraventricular arrhythmias was extremely low, which suggested an extensive atrial arrhythmogenic substrate due to substantial and progressive AMA-M2-associated damage to the atrial myocardium.

Discussion

Here, for the first time, we clarify the prevalence of supraventricular arrhythmias in unselected AMA-M2-positive patients. The prevalence of supraventricular arrhythmias in AMA-M2-positive patients was 14%, which was significantly higher than that in AMA-M2-negative patients. The multivariate analysis revealed that the presence of AMA-M2 was an independent risk factor for supraventricular arrhythmias in the present patient cohort. The supraventricular arrhythmias that were associated with AMA-M2 were also characterized.

The association between AMA-M2 and supraventricular arrhythmias

To date, limited data have been available on the independent association between AMA-M2 and supraventricular arrhythmias. Maeda et al. reported 5 (21%) patients with supraventricular arrhythmias among 24 patients with AMA-M2-associated myopathy (5). In contrast to their cohort, we included all of the AMA-M2-positive patients, irrespective

of their history of myopathy or CK values, in order to determine the prevalence of supraventricular arrhythmias in unselected AMA-M2-positive patients. Supraventricular arrhythmias were found in 14% of the AMA-M2-positive patients. As shown in Table 2, the CK level did not differ between the AMA-M2-positive and AMA-M2-negative patients, suggesting that our patient cohort did not include a substantial number of patients with clinically significant AMA-M2-associated myopathy. Furthermore, the multivariate analyses revealed that AMA-M2 was associated with supraventricular arrhythmias, even when the CK level was included in the model (Table 6). Considering these results, AMA-M2 appears to be independently associated with supraventricular arrhythmias, irrespective of skeletal muscular involvement.

The AMA-M2 titer of the AMA-M2-positive patients did not differ to a statistically significant extent, regardless of the absence or presence of supraventricular arrhythmias. In contrast, a previous study reported that arrhythmias tended to be more frequent in patients with a high AMA-M2 titer (5). Thus, further observation is required to clarify the association between the AMA-M2 titer and the progression of cardiac involvement, including the frequency of supraventricular arrhythmias.

The preferential involvement of the atrium

In the present study, the prevalence of supraventricular arrhythmias was higher than that of ventricular arrhythmias; this result was compatible with a previous report (5). This

Figure. A representative case of multiple supraventricular arrhythmias in an anti-mitochondrial M2 antibody-positive patient. (A) A V1 lead electrocardiogram showing atrial fibrillation with low amplitude fibrillation waves. (B) Atrial tachycardia is confirmed in the V1 lead. Note the low amplitude of the regular ectopic P-waves. (C) Atrial standstill with an escape rhythm demonstrated in the V1 lead. (D) The apical four-chamber view of the echocardiographic examination in systole showing dilation of both atria (left atrial diameter: 53×61 mm, right atrial diameter: 49×60 mm).

suggests that substantial degeneration occurred in the atrial myocardium, which might work as a substrate for supraventricular arrhythmias. To the best of our knowledge, however, few reports have demonstrated atrial myocardial involvement in a convincing fashion. We consider that a high prevalence of supraventricular arrhythmias might, in part, be explained by the difference in the myocardial wall between the atria and ventricles. As the atrial wall is considerably thinner than the ventricular wall, it might be susceptible to a smaller degree of damage, manifesting as the preferential involvement of the atrium. The left atrial enlargement that was observed in AMA-M2-positive patients (Table 4) may support this hypothesis.

A possible mechanism of AMA-M2-associated myocardial involvement and supraventricular arrhythmias

Among the nine AMAs, AMA-M7 has been detected in patients with acute and chronic cardiomyopathies (12, 13). AMA-M2 was also found in some cardiomyopathy patients (6, 7). Notably, Varga et al. described the presence of skeletal mitochondrial damage without significant inflammation in PBC patients (14), suggesting a direct disturbance of the muscular energy metabolism by the AMAs. Conversely, several reports have demonstrated inflammation due to cellular immunological mechanisms (15). In particular, Matsmoto et al. revealed the interstitial infiltration of CD3-positive T cells in the ventricular myocardium of a patient with AMA-M2-associated cardiomyopathy (6), and Shimizu et al. reported the predominant infiltration of CD4-positive T cells in the skeletal muscles of a patient with AMA-M2-associated myopathy (8). Although the mechanism of AMA-M2-associated myopathy has yet to be clarified, these observations suggest that mitochondrial dysfunction due to humoral autoimmunity and cellular autoimmunity maintained

by autoreactive T cells may be involved in the mechanism of AMA-M2-associated myocardial involvement and the resultant supraventricular arrhythmias. In addition, individual variations in the immunological system and certain viral infections may also play important roles in producing pathogenic autoantibodies, which might trigger chronic autoimmunity against multiple organs (16).

Finally, Keresztes et al. reported that autonomic nerve dysfunction is a frequent complication in PBC patients (17). Specifically, their findings from an analysis of 24-hour heart rate variability indicated a synchronic impairment of the parasympathetic and sympathetic systems. As the autonomic nervous system is closely associated with the occurrence of AF and SSS (18), autonomic nerve dysfunction might influence the triggering of supraventricular arrhythmias in AMA-M2-positive patients.

Clinical implications

The results of this study demonstrated that the presence of AMA-M2 is an independent risk factor for supraventricular arrhythmias, including AF, AFL, AT, SSS, and atrial standstill. Although we were unable to confirm the latent electrical remodeling of the atria by our subgroup analysis of the 12-lead ECG data of the AMA-M2-positive patients (Table 3), periodical ECGs are recommended to avoid missing any asymptomatic supraventricular arrhythmias. Considering the fact that a number of AMA-M2-positive patients associated with PBC are currently managed by hepatologists, referral to cardiology should be considered in patients with arrhythmias. In turn, cardiologists need to suspect AMA-M2-associated myopathy and PBC, when middle-aged women with elevated hepatobiliary enzymes present with characteristic supraventricular arrhythmias, as shown in Figure.

Based on the supposition that AMA-M2 related atrial in-

involvement would likely be progressive, our finding suggested a potential need for anticoagulation therapy or pacemaker implantation during the clinical course of patients who are positive for AMA-M2. To date, however, no guidelines that have focused on these supraventricular arrhythmias exist for the management of AMA-M2-positive patients. We therefore highlight the need for physicians to pay attention to supraventricular arrhythmias in AMA-M2-positive patients. Considering the likelihood that autoimmunity might be involved in the development of these supraventricular arrhythmias, immunosuppressive therapy, including glucocorticoids (6), might represent a better therapeutic option for suppressing these arrhythmias than anti-arrhythmic agents. If used, immunosuppressive therapy should be initiated as early as possible to limit disease progression.

The present results also highlighted a need for physicians to update their knowledge of AMAs, as well as to keep abreast of the current nomenclature and guidelines for the disease entity that is referred to as “primary biliary cirrhosis”. The term, “primary biliary cirrhosis,” is being replaced by “primary biliary cholangitis” because the conventional term does not accurately reflect the natural history of disease in the vast majority of patients (19). In the latest guidelines, histological findings are not necessarily indispensable in the diagnosis of PBC. The presence of AMAs accompanied by clinical features and a course of classical and cholestatic PBC are required, including increased levels of serum ALP and γ -GTP (20).

Study limitations

Our study is associated with several potential limitations. First, a selection bias could not be avoided in our patient cohort because the present observational study was conducted retrospectively. In particular, the 12-lead ECG and echocardiographic data were retrospectively available for only 64% and 40% of the patients, respectively. The subgroup results in Tables 3 and 4 should therefore be confirmed in future studies. Second, because the present study was conducted in a single center, the patient population was relatively small. Thus, the present results may not be representative of AMA-M2-positive patients in the general population. Our results should therefore be verified using a prospective and multi-center study design. Third, supraventricular arrhythmias are frequently asymptomatic. Thus, we cannot deny the possibility of the underestimation of their prevalence. Finally, although our close observation of supraventricular arrhythmias and the echocardiographic subanalysis suggested extensive atrial myocardial damage, we were unable to perform a biopsy of the atrial thinner musculature in most cases and it was difficult to directly detect inflammation or fibrosis of the atrium. Further studies based on intraoperatively obtained specimens, autopsy results, electroanatomic mapping, ^{18}F isotope-labeled positron emission tomography, metaiodobenzylguanidine myocardial scintigraphy, and delayed enhancement magnetic resonance imaging would likely have the potential to elucidate the

mechanism of supraventricular arrhythmias in patients with AMA-M2-associated cardiomyopathy.

Conclusion

The present study revealed that the prevalence of supraventricular arrhythmias represented one seventh of the patients with positive AMA-M2 test results. Furthermore, AMA-M2 conferred a substantial risk of supraventricular arrhythmias, suggesting that atrial myocardial involvement and the formation of an arrhythmogenic substrate. Physicians should maintain awareness of supraventricular arrhythmias in AMA-M2-positive patients.

Author's disclosure of potential Conflicts of Interest (COI).

Koji Fukuzawa: Research funding, Medtronic Japan and St. Jude Medical Japan. Kunihiro Kiuchi: Research funding, Medtronic Japan and St. Jude Medical Japan. Ken-ichi Hirata: Research funding, Medtronic Japan and St. Jude Medical Japan.

References

1. Frostell A, Mendel-Hartvig I, Nelson BD, et al. Mitochondrial autoantigens in primary biliary cirrhosis. Association of disease-specific determinants with a subunit of complex I (NADH-ubiquinone reductase) of the inner mitochondrial membrane. *Scand J Immunol* **28**: 645-652, 1988.
2. Berg PA, Klein R. Mitochondrial antigens and autoantibodies: from anti-M1 to anti-M9. *Klin Wochenschr* **64**: 897-909, 1986.
3. Bassendine MF, Jones DE, Yeaman SJ. Biochemistry and autoimmune response to the 2-oxoacid dehydrogenase complexes in primary biliary cirrhosis. *Semin Liver Dis* **17**: 49-60, 1997.
4. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. *N Engl J Med* **353**: 1261-1273, 2005.
5. Maeda MH, Tsuji S, Shimizu J. Inflammatory myopathies associated with anti-mitochondrial antibodies. *Brain* **135**: 1767-1777, 2012.
6. Matsumoto K, Tanaka H, Yamana S, et al. Successful steroid therapy for heart failure due to myocarditis associated with primary biliary cirrhosis. *Can J Cardiol* **28**: 515 e3-e6, 2012.
7. Uenaka T, Kowa H, Sekiguchi K, et al. Myositis with antimitochondrial antibodies diagnosed by rectus abdominis muscle biopsy. *Muscle Nerve* **47**: 766-768, 2013.
8. Shimizu J. Clinical and histopathological feature of myositis associated with anti-mitochondrial antibodies. *Rinsho Shinkeigaku. Clin Neurol* **53**: 1114-1116, 2013 (in Japanese, Abstract in English).
9. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. *JAMA* **285**: 2864-2870, 2001.
10. Japan Nephrology Society. Special issue: Clinical practice guideline for diagnosis and treatment of chronic kidney disease 2012. *Nihon Jinzo Gakkai Shi* **54**: 1034-1191, 2012 (in Japanese).
11. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. *J Am Soc Echocardiogr* **28**: 1-39, 2015.
12. Klein R, Maisch B, Kochsiek K, Berg PA. Demonstration of organ specific antibodies against heart mitochondria (anti-M7) in sera from patients with some forms of heart diseases. *Clin Exp Immunol* **58**: 283-292, 1984.

13. Otto A, Stähle I, Klein R, Berg PA, Pankuweit S, Brandsch R. Anti-mitochondrial antibodies in patients with dilated cardiomyopathy (anti-M7) are directed against flavoenzymes with covalently bound FAD. *Clin Exp Immunol* **111**: 541-547, 1998.
14. Varga J, Heiman-Patterson T, Muñoz S, Love LA. Myopathy with mitochondrial alterations in patients with primary biliary cirrhosis and antimitochondrial antibodies. *Arthritis Rheum* **36**: 1468-1475, 1993.
15. Berg PA. The role of the innate immune recognition system in the pathogenesis of primary biliary cirrhosis: a conceptual view. *Liver Int* **31**: 920-931, 2011.
16. Pender MP. CD8+ T-cell deficiency, Epstein-Barr virus infection, vitamin D deficiency, and steps to autoimmunity: a unifying hypothesis. *Autoimmune Dis* **2012**: 189096, 2012.
17. Keresztes K, Istenes I, Folhoffer A, et al. Autonomic and sensory nerve dysfunction in primary biliary cirrhosis. *World J Gastroenterol* **10**: 3039-3043, 2004.
18. Chen PS, Tan AY. Autonomic nerve activity and atrial fibrillation. *Heart Rhythm* **4**: S61-S64, 2007.
19. Beuers U, Gershwin ME, Gish RG, et al. Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'. *Hepatology* **62**: 1620-1622, 2015.
20. Working Subgroup (English version) for Clinical Practice Guidelines for Primary Biliary Cirrhosis. Guideline for the management of primary biliary cirrhosis. The Intractable Hepatobiliary Disease Study Group supported by the Ministry of Health, Labour and Welfare of Japan. *Hepatol Res* **44** (Suppl S1): 71-90, 2014.

The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (<https://creativecommons.org/licenses/by-nc-nd/4.0/>).